Johnson & Johnson Cert.Deposito Arg.Repr. 0.2 Shs für 0 Euro bei ZERO ordern (zzgl. Spreads)

ISIN: ARDEUT110236

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV		Knock-Outs
Historisch			Analysen

Kurse + Charts + Realtime
Kurs + Chart
Chart (groß)
Times + Sales
Chartvergleich
Börsenplätze
Realtime Push
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Aktion
Portfolio
Watchlist

Nachrichten zu Johnson & Johnson Cert.Deposito Arg.Repr. 0.2 Shs

11.03.26		Einblick ins Bridgewater-Depot: Die Top-Aktien aus dem vierten Quartal 2025 (finanzen.at) Im 4. Quartal 2025 gab es viel Bewegung im Portfolio von Bridgewater Associates: Keine der zehn größten Aktienbeteiligungen des von Ray Dalio gegründeten Hedgefonds blieb unverändert.» mehr
03.03.26		Commerzbank-Portfolio: Diese US-Aktien gehörten im vierten Quartal 2025 zu den größten Positionen (finanzen.at) Im vierten Quartal 2025 hat die Commerzbank einige Änderungen an ihren US-Beteiligungen vorgenommen. Diese Aktien schafften es im Depot nun unter die Top Ten.» mehr
26.02.26		Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer (EN, Johnson & Johnson)
26.02.26		Johnson & Johnson Completes Catheter Portfolio with Launch of CEREGLIDE™ 42, CEREGLIDE™ 57, and INNERGLIDE™ 7 (EN, Johnson & Johnson)
24.02.26		Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA) (EN, Johnson & Johnson)
23.02.26		Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer (EN, Johnson & Johnson)
21.02.26		TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years (EN, Johnson & Johnson)
19.02.26		RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer (EN, Johnson & Johnson)
18.02.26		Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania (EN, Johnson & Johnson)
18.02.26		Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania (EN, Johnson & Johnson)
18.02.26		RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer (EN, Johnson & Johnson)
17.02.26		FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month (EN, Johnson & Johnson)
07.02.26		Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium (EN, Johnson & Johnson)
03.02.26		Johnson & Johnson Releases Report on Surgeon Burnout as More than 40% Surveyed Consider Leaving the Profession (EN, Johnson & Johnson)
03.02.26		Johnson & Johnson Highlights New Scientific Evidence and Reinforces its Leadership with Portfolio Advancements at AF Symposium (EN, Johnson & Johnson)
27.01.26		DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible (EN, Johnson & Johnson)
27.01.26		Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile (EN, Johnson & Johnson)
21.01.26		Johnson & Johnson reports Q4 and Full-Year 2025 results (EN, Johnson & Johnson)
16.01.26		New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder (EN, Johnson & Johnson)
15.01.26		Johnson & Johnson Introduces Mobile Simulator App to Support Breast Augmentation Patients (EN, Johnson & Johnson)
13.01.26		Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting (EN, Johnson & Johnson)
10.01.26		RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer (EN, Johnson & Johnson)
09.01.26		Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments (EN, Johnson & Johnson)
08.01.26		Johnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award (EN, Johnson & Johnson)
07.01.26		Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (EN, Johnson & Johnson)
06.01.26		Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study (EN, Johnson & Johnson)
29.12.25		Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies (EN, Johnson & Johnson)
22.12.25		European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor (EN, Johnson & Johnson)
19.12.25		Johnson & Johnson Backs HRS Registry to Advance Real-World Evidence in PFA (EN, Johnson & Johnson)
18.12.25		Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma (EN, Johnson & Johnson)
13.12.25		U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care* (EN, Johnson & Johnson)
06.12.25		Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma (EN, Johnson & Johnson)
05.12.25		Johnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC (EN, Johnson & Johnson)
03.12.25		Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40 (EN, Johnson & Johnson)
17.11.25		New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis (EN, Johnson & Johnson)
17.11.25		Johnson & Johnson set to revolutionize the treatment of cancer with the acquisition of Halda Therapeutics (EN, Johnson & Johnson)
10.11.25		L.A. Lakers coach JJ Redick lists his Brooklyn ‘trophy’ penthouse for $6.2 million (MarketWatch)
06.11.25		DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma (EN, Johnson & Johnson)
06.11.25		FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder (EN, Johnson & Johnson)
04.11.25		Johnson & Johnson reinforces its leadership in hematology at ASH 2025 unveiling new paradigm-shifting research (EN, Johnson & Johnson)
04.11.25		Johnson & Johnson One Year Data Demonstrate Durable Performance and Safety of the Shockwave Javelin Peripheral IVL Catheter in Late-Breaking Presentation at VIVA 2025 (EN, Johnson & Johnson)
03.11.25		Johnson & Johnson Confirms Durability of IVL in Complex, Below-the-Knee Anatomy in Late-Breaking Presentation at VIVA 2025 (EN, Johnson & Johnson)
03.11.25		Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS (EN, Johnson & Johnson)
31.10.25		Johnson & Johnson submits application to U.S. FDA for STELARA® (ustekinumab) in the treatment of pediatric ulcerative colitis (EN, Johnson & Johnson)
29.10.25		Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting (EN, Johnson & Johnson)
28.10.25		Johnson & Johnson to Advance Robotics Development with NVIDIA Isaac for Healthcare (EN, Johnson & Johnson)
27.10.25		New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile (EN, Johnson & Johnson)
27.10.25		Johnson & Johnson Advances Polyphonic™ AI Fund for Surgery for Data-Driven Healthcare (EN, Johnson & Johnson)
27.10.25		TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years (EN, Johnson & Johnson)
27.10.25		Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis (EN, Johnson & Johnson)

1 | Weiter

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	17.03.2026 22:21
Kaufwert:	EUR
	Hinzufügen Speichern

ISIN: ARDEUT110236

Nachrichten zu Johnson & Johnson Cert.Deposito Arg.Repr. 0.2 Shs

Newssuche

Meistgelesene Nachrichten

Johnson & Johnson Cert.Deposito Arg.Repr. 0.2 Shs Aktie

ISIN: ARDEUT110236

Nachrichten zu Johnson & Johnson Cert.Deposito Arg.Repr. 0.2 Shs

Newssuche

Meistgelesene Nachrichten